AIM IMMUNOTECH INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AIM IMMUNOTECH INC. (AIM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $80.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-11-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2024-11-14
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $80.00K, a 60.00% increase year-over-year.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $80.00K, a 2.44% decline year-over-year.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-12-31 was $61.00K, a 62.35% decline year-over-year.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $50.00K, a 81.82% decline year-over-year.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $243.00K, a 74.53% decline from fiscal 2022.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $954.00K, a 39.16% decline from fiscal 2021.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $1.57M, a 51.35% increase from fiscal 2020.
- AIM IMMUNOTECH INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $1.04M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2024-06-30 | $80.00K 10-Q · filed 2024-11-14 | $160.00K derived: sum of 2 quarters · filed 2024-11-14 | $221.00K derived: sum of 3 quarters · filed 2024-11-14 | $271.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $80.00K 10-Q · filed 2024-11-14 | $141.00K derived: sum of 2 quarters · filed 2024-11-14 | $191.00K derived: sum of 3 quarters · filed 2024-11-14 | $241.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $111.00K derived: sum of 2 quarters · filed 2024-04-01 | $161.00K derived: sum of 3 quarters · filed 2024-08-14 | $243.00K 10-K · filed 2024-04-01 |
| 2023-09-30 | $50.00K 10-Q · filed 2023-11-14 | $100.00K derived: sum of 2 quarters · filed 2024-08-14 | $182.00K 10-Q · filed 2023-11-14 | $344.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $50.00K 10-Q · filed 2024-08-14 | $132.00K derived: sum of 2 quarters · filed 2024-08-14 | $294.00K derived: sum of 3 quarters · filed 2024-08-14 | $569.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $82.00K 10-Q · filed 2024-08-14 | $244.00K derived: sum of 2 quarters · filed 2024-08-14 | $519.00K derived: sum of 3 quarters · filed 2024-08-14 | $794.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2022-12-31 | $162.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $437.00K derived: sum of 2 quarters · filed 2024-04-01 | $712.00K derived: sum of 3 quarters · filed 2024-04-01 | $954.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $275.00K 10-Q · filed 2023-11-14 | $550.00K derived: sum of 2 quarters · filed 2023-11-14 | $792.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $275.00K 10-Q · filed 2023-08-14 | $517.00K derived: sum of 2 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $242.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $1.57M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $314.00K 10-Q · filed 2022-11-14 | $794.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.32M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $480.00K 10-Q · filed 2022-11-14 | $1.01M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $526.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $1.04M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $250.00K 10-Q · filed 2021-11-15 | $400.00K derived: sum of 2 quarters · filed 2021-11-15 | $596.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $150.00K 10-Q · filed 2021-11-15 | $346.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $196.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |